Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
A study of the new drug Lonsurf in gastric cancer found that the treatment was tolerable and improved overall survival in patients... Read More
Safety of TAS-102 in Patients With Metastatic Gastric/GE Junction and Colorectal Cancer
Lonsurf was well tolerated and associated with no major toxicities in two trials with 850 gastric cancer patients, said Cambridge doctor Lizzy... Read More
FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer
Shared in OncLive, the FDA has granted priority review to a supplemental new drug application for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in... Read More
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Lonsurf receives FDA priority review for metastatic gastric cancer, with a new study presented at ESMO 2018 Congress and published in The... Read More
